Fipaxalparant

DRUG3 trials

Sponsors

Horizon Therapeutics Ireland Designated Activity Company

Conditions

Diffuse Cutaneous Systemic SclerosisIdiopathic Pulmonary Fibrosis

Phase 2

A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

CompletedCTIS2023-509784-24-00

Horizon Therapeutics Ireland Designated Activity CompanyIdiopathic Pulmonary Fibrosis

Start: 2022-05-11End: 2024-10-30Target: 17Updated: 2024-12-18

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301]

CompletedCTIS2023-509782-20-00

Horizon Therapeutics Ireland Designated Activity CompanyDiffuse Cutaneous Systemic Sclerosis

Start: 2021-11-11End: 2024-12-19Target: 84Updated: 2025-02-25

A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

CompletedCTIS2023-509783-23-00

Horizon Therapeutics Ireland Designated Activity CompanyDiffuse Cutaneous Systemic Sclerosis

Start: 2023-02-24End: 2024-12-18Target: 167Updated: 2025-02-14